Changzhou Qianhong Bio-pharma Co., Ltd., a leading biochemical maker of polysaccharides and enzyme drugs, has started construction on phase two of its pharmaceuticals production facility at Changzhou National Hi-Tech District.
With an investment of 1 billion yuan ($146 million), the phase two project adds 200 million tablets and 60 million injections to production as well as making molecular diagnosis reagents available for use by 20 million people.
The company is a major manufacturer of pancreatic kininogenase, heparin sodium, and low molecular weight heparin, as well as compound digestive enzyme preparations and asparaginase, all of which had, prior to the roll out of its phase one facility, never been produced in China.
Several products have been granted quality certifications by governing bodies in the U.S., the EU, and Japan. The company has set up an international marketing network, with products being sold in more than 20 provinces and cities across China as well as exported to markets abroad.
The phase two development will focus on the research and development of innovative and first-of-its-class-in-China biological drugs with its own intellectual property rights, and with the aim of treating patients with critical illnesses, including cancer, cardiovascular, and cerebrovascular diseases.